GSK's Trelegy Ellipta meets key goal in late-stage asthma study
May 02, 2019 at 13:20 PM EDT
British drugmaker GlaxoSmithKline Plc said on Thursday that its respiratory drug Trelegy Ellipta met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines division that has been hit by generic competition.